Similar to gene therapy, antisense oligonucleotides (ASOs) target mutant RNA transcripts associated with ALS. These short DNA or RNA molecules bind to specific RNA sequences, preventing them from being translated into harmful proteins. Several ASOs are undergoing clinical trials for the treatment of ALS, with some showing early signs of effectiveness in slowing disease progression.